Rubella virus usually causes a mild fever and rash in children and adults.* However, infection during pregnancy, especially during the first trimester, can result in miscarriage, stillbirth, or infants with congenital malformations, known as congenital rubella syndrome (CRS). In 2011, the World Health Organization (WHO) updated guidance on the preferred strategy for introduction of rubella-containing vaccine (RCV) into national routine immunization schedules with an initial wide-age-range vaccination campaign that includes children aged 9 months-15 years (1) . WHO also urged all member states to take the opportunity offered by accelerated measles control and elimination activities as a platform to introduce RCVs (1) . The Global Measles and Rubella Strategic Plan respectively. AMR has started to document the elimination of measles, rubella, and CRS; in EUR, rubella incidence has decreased significantly, although outbreaks continue to occur.
Immunization Activities
Data were obtained from the WHO and United Nations Children's Fund (UNICEF) Joint Reporting Form (JRF), which is used to collect information from United Nations member states on vaccination campaigns, vaccination schedules, and number of doses of RCV administered by routine immunization services (2) . Data from 2000-2012 were analyzed to assess the changes in rubella and CRS control activities.
As Of 132 member states that have introduced RCV, 124 (94%) provide the first RCV dose with the first routine dose of measles-containing vaccine (MCV) and eight (6%) provide the first RCV dose with the second MCV dose. In 2012, the first RCV dose was administered at age 9 months in eight (6%) member states, age 12-18 months in 120 (91%) member states, and age >18 months in three (3%) member states. RCV is provided in combination with measles vaccine alone in 11% of member states and in combination with measles and mumps (with or without varicella vaccine) in 89% of member states.
Surveillance Activities
Rubella and CRS surveillance are necessary to evaluate the disease burden before and after introduction of RCV, and to identify pregnant women infected with rubella and children with CRS who require follow-up. The JRF collects surveillance data from member states, including cases of rubella and congenital rubella syndrome; for this report, data from 2000-2012 were analyzed. WHO has published case definitions for rubella and CRS as recommended standards for member state reporting (3 
Editorial Note
Following a period of steady but slow increases in rubella control, a new phase of accelerated rubella control and CRS prevention has begun, marked by the 2011 WHO position paper recommending a strategy to eliminate rubella and CRS, and emphasizing RCV introduction in all member states and the linkage of rubella to measles control activities. Programmatic integration of RCV into an existing measles schedule is straightforward, involving no increase in the number of injections or in cold-chain requirements with a combined measles-rubella vaccine, no change in age of vaccine administration, and minimal change in recording and reporting formats. Sustainable financing from government and partners is required to introduce and maintain routine rubella immunization activities and inclusion of RCV for all measles campaigns following introduction. The additional cost to include the rubella antigen with the measles vaccine is 0.199 to 0.309 U.S. dollars per dose. ¶ GAVI Alliance funding is available for eligible member states to support introduction; the funding supports a grant for introduction of RCV into the national routine immunization schedule and a wide-age-range RCV campaign. Nine member states applied for these funds in 2012. For RCV introduction to succeed, decision makers need to identify rubella and CRS as a public health priority, provide sustainable support, and ensure adequate coverage. Suboptimal implementation of rubella control strategies might result in an increase in CRS cases; following years of low vaccine coverage and lower levels of rubella virus transmission, persons who would have been infected as children remain susceptible until they reach adolescence and adulthood, resulting in a potential increase in CRS cases, as seen in Greece (7). To prevent an increase in rubella and CRS, the preferred RCV introduction strategy is to first conduct a national wide-age-range campaign and then immediately introduce RCV into the routine immunization schedule. Postcampaign coverage surveys validate the campaign coverage and can identify potential gaps.
Activities to reach elimination goals in AMR and EUR have decreased the number of cases in 2012 relative to 2000. Improvements in surveillance have not been consistent between member states and WHO regions. Improved surveillance for rubella in AFR and SEAR has increased the number of rubella cases detected that previously would have been undetected. Strong reporting systems in WPR and EUR resulted in a greater proportion of the cases reported globally. In AMR, a clear decrease in rubella cases is associated with a decrease in CRS cases.
Outbreaks in EUR and WPR indicate that while control and elimination activities are ongoing, some member states within these regions are at risk for large outbreaks. Initiation of CRS control activities focused on vaccinating girls and women, which decreased rubella virus transmission but resulted in a large proportion of susceptible persons, especially males. A large population susceptible to rubella infection (primarily males) has a high risk for outbreak and transmission of rubella virus to unvaccinated pregnant women. Surveillance for rubella infection benefits from integration with measles surveillance systems, but additional effort is required to strengthen the system to ensure that febrile rash illness cases reported in pregnant women or their immediate contacts are fully investigated, including ascertaining pregnancy outcome. Surveillance to detect CRS is needed to monitor the impact of vaccination.
The difference between the 2012 global coverage with the first dose of MCV (83%) and RCV (43%) highlights the extent of the opportunity missed by the lack of integration of RCV with MCV. With a new phase of rubella control, member states should consider introducing or strengthening RCVs immunization activities and strengthening their existing rubella and CRS surveillance systems. The availability of technical expertise and financial resources from Measles Rubella Initiative partners, including the GAVI Alliance, provides a foundation to accelerate rubella control and CRS prevention activities globally. In addition, political commitment at the federal, provincial, and district levels is needed to reach the Measles Rubella Initiative and Global Vaccine Action Plan goal of elimination in five WHO regions by 2020.
